Navigating Shoulder Arthroplasty: From Implant Choices to Financial Pressure

From Implant Choices to Financial Pressure

Orthopedic Surgery · Seminar week 37 · released October 1, 2026 · includes a discussion video

Given the technological advancements and financial pressures influencing orthopedic care, particularly in shoulder arthroplasty, seminars like those based on P36 (Robotic…

Learning Objectives

• Differentiate indications for anatomic total shoulder arthroplasty, reverse total shoulder arthroplasty, and hemiarthroplasty.
• Interpret rotator-cuff status, glenoid morphology, bone quality, and functional goals when selecting an implant.
• Appraise the evidence for three-dimensional planning, navigation, patient-specific instrumentation, and true robotic assistance.
• Distinguish implant price, hospital cost, charge, reimbursement, and total episode-of-care value.
• Apply outpatient-selection, infection-prevention, blood-management, analgesia, and rehabilitation protocols safely.
• Explain how Medicare site-of-service, prior-authorization, registry, and payment policies influence practice.
• Construct a clinically defensible and financially responsible arthroplasty plan through shared decision-making.

Current Trends in Shoulder Arthroplasty

%%FIG0%% Shoulder arthroplasty is no longer one operation for one disease. Utilization has risen rapidly, with reverse total shoulder arthroplasty—rTSA or RSA—driving most growth. A US analysis found that population-adjusted RSA incidence increased from 7.3 to 19.3 per 100,000 between 2012 and 2017, while anatomic TSA increased more modestly and hemiarthroplasty declined (PMID: 32858194). Registry analyses subsequently documented continued growth and expansion of reverse constructs beyond cuff-tear arthropathy into fracture, revision, severe glenoid deformity, fixed stiffness, and selected cuff-intact osteoarthritis (PMID: 38888103). This expansion reflects improved implants and surgeon familiarity, but it has moved faster than randomized comparative evidence.

MUST ACT: Confirm that the glenohumeral joint is the dominant pain generator before discussing implant geometry. Cervical radiculopathy, rotator-cuff disease without arthritis, adhesive capsulitis, acromioclavicular pathology, inflammatory arthritis, neuropathic arthropathy, and occult infection can imitate or coexist with end-stage osteoarthritis.

The minimum evaluation includes the duration and location of pain, night symptoms, functional loss, prior instability or surgery, injections, opioid exposure, and response to reasonable nonoperative care. Examine active and passive motion separately. Weak active elevation with preserved passive elevation suggests cuff failure or neurologic dysfunction; global restriction of both may reflect arthritis, capsular contracture, or fixed deformity. Test the subscapularis, posterosuperior cuff, deltoid, and axillary nerve. Obtain a true anteroposterior/Grashey view and an axillary view; the latter is essential for recognizing posterior decentering. Thin-cut CT with three-dimensional reconstruction defines glenoid version, inclination, vault support, posterior wear, and Walch morphology. MRI or high-quality ultrasound is useful when cuff integrity or fatty infiltration remains uncertain.

Anatomic TSA restores a native ball-and-socket relationship. It generally provides reliable pain relief and preserves rotation when the cuff—including a functional or securely repairable subscapularis—can center the humeral head. Cuff failure permits eccentric translation and “rocking-horse” loading of the glenoid, leading to instability or loosening. Reverse TSA changes the center of rotation and increases the deltoid lever arm, permitting deltoid-driven elevation when cuff mechanics cannot provide a stable fulcrum. It still requires a functioning deltoid and axillary nerve, adequate glenoid fixation, and appropriate soft-tissue tension.

Teaching Point: Reverse TSA compensates for deficient cuff mechanics; it does not recreate normal shoulder biomechanics. Its characteristic problems—instability, acromial or scapular-spine stress fracture, notching, infection, and baseplate failure—differ from the glenoid loosening, polyethylene wear, and late cuff or subscapularis failure seen after anatomic TSA.

Cuff-intact osteoarthritis is the major overlap zone. In a matched observational study of 740 shoulders, anatomic and reverse procedures produced similar short-term outcomes; anatomic TSA provided greater external rotation, while complications were 4.9% versus 2.2% and revision rates were not significantly different (PMID: 36135928). Selection bias prevents causal conclusions. RAPSODI-UK is a pragmatic randomized trial designed to compare clinical and cost effectiveness in adults aged at least 60 years with cuff-intact osteoarthritis; its ongoing status underscores genuine equipoise rather than established reverse superiority (PMID: 41386993).

Implant evolution should be matched to a defined problem. Cemented all-polyethylene glenoids remain a defensible anatomic benchmark; older metal-backed designs demonstrated higher revision despite fewer radiolucent lines (PMID: 24951741). Stemless and short-stem humeral components preserve bone but require sound metaphyseal bone. Randomized-trial meta-analysis has not shown important functional, fracture, or revision advantages over conventional stems (PMID: 36322637). Posteriorly augmented glenoids and augmented reverse baseplates may preserve bone when eccentric reaming would medialize the joint line or compromise the vault. Lateralized reverse constructs may reduce impingement and improve rotation, but excessive lateralization increases acromial loading and glenoid shear.

Decision Point: Can the humeral head be recentered and component support restored without sacrificing essential subchondral bone? If not, preserving “anatomic” geometry may be anatomically—and economically—false economy.

Audience Poll: For a 72-year-old with cuff-intact osteoarthritis and a B2 glenoid, which most strongly influences your choice: chronological age, cuff quality, correctability of posterior subluxation, activity goals, or implant price?

Robotic Assistance Versus Conventional Techniques

%%FIG1%% “Computer-assisted” shoulder arthroplasty encompasses several distinct technologies. Three-dimensional planning converts thin-cut CT data into a virtual scapular and humeral model on which the surgeon selects implant size, version, inclination, offset, augment, and screw trajectories. Patient-specific instrumentation, or PSI, transfers part of that plan through a custom guide, usually controlling the central pin but not necessarily reaming depth or every subsequent step. Optical navigation tracks instruments and anatomy in real time. A true robotic system adds a powered or mechanically constrained arm that helps execute a planned cut, pin trajectory, or reaming path. None is autonomous, and none determines the correct operation.

Accuracy matters because glenoid exposure is restricted and arthritic erosion distorts landmarks. In anatomic TSA, excessive residual retroversion or unsupported seating can produce posterior edge loading and loosening. In reverse TSA, an excessively superior starting point, inadequate inferior overhang, poor screw purchase, or unintended tilt can contribute to impingement, notching, instability, or baseplate failure. Yet accuracy is not equivalent to clinical wisdom: there is no universally optimal version, inclination, lateralization, or correction target across all anatomies and implant designs.

Nuance: A robot can execute the wrong plan with exquisite precision. Cuff and deltoid function, bone quality, implant design, joint-line restoration, and soft-tissue tension still determine whether an accurately placed component works.

The strongest clinical accuracy evidence largely concerns navigation, not robotics. In a small prospective randomized study of 20 anatomic TSAs, navigation produced greater correction of glenoid retroversion but increased mean operative time from approximately 138 to 170 minutes (PMID: 19559369). Later observational studies found tighter dispersion of component position, longer screws, or fewer screws with navigation, but durable improvements in patient-reported outcomes, revision, or survivorship remain unproven. A 2026 meta-analysis found that navigation improved external rotation and several scores by small amounts while producing no significant differences in most other motion or outcome measures; included studies were nonrandomized and at moderate risk of bias (PMID: 41858488).

PSI evidence is similarly mixed. A seven-center randomized trial of 106 primary reverse TSAs found no improvement in baseplate version, inclination, or positional offset over freehand instrumentation, although several peripheral-screw metrics improved (PMID: 41407028). A broader meta-analysis found favorable changes in some radiographic measures but no significant improvement in short-term complications, operative duration, or Constant score (PMID: 40241855). These results argue against purchasing PSI solely on a claim of universally superior placement.

True robotic shoulder arthroplasty is earlier in its evidence life cycle. The FDA cleared the ROSA Shoulder System in 2024 as stereotaxic instrumentation incorporating a robotic arm and optical navigation (FDA K233199). Bench testing has shown smaller deviations from planned version and inclination than manual instrumentation, but bone-model accuracy is not a patient outcome (PMID: 39863156). As of July 2026, there are no randomized comparative clinical trials demonstrating that true shoulder robotics improves pain, function, complications, revision, or implant survival.

A safe robotic workflow begins with a high-quality CT, segmentation review, and a surgeon-approved plan. Intraoperatively, secure tracker placement and meticulous registration are followed by confirmation at an independent bony checkpoint. Registration must be rechecked after any tracker impact or implausible display. Failure modes include CT segmentation error, cartilage or soft tissue obscuring landmarks, tracker motion, loss of optical line of sight, coracoid pin complications, retractor-arm collision, implant incompatibility, and platform failure.

MUST ACT: If computer guidance conflicts with visible anatomy, stop. Verify the tracker and registration, re-register if necessary, and convert to conventional instrumentation when uncertainty persists. A complete manual bailout set must be available.

The most defensible use is selective: severe B2/B3 or dysplastic glenoids, small vaults, revision bone loss, or anatomy in which the technology materially changes augment selection, reaming, or screw strategy. Routine use in straightforward anatomy requires a separate value argument that includes capital cost, service contracts, disposables, CT and segmentation, training, operating-room time, downtime, and vendor lock-in.

Framework: Ask three questions before using an enabling technology: Does it change the plan? Does it reduce a clinically meaningful risk? Is that benefit supported by patient-outcome evidence rather than a radiographic surrogate?

Audience Poll: Would you approve robotic assistance for all primary shoulder arthroplasties, only complex glenoids, only within a registry or trial, or not until comparative outcome data mature?

Financial Pressures and Clinical Decision-Making

%%FIG2%% Cost, charge, payment, and value are not interchangeable. Cost is the resource consumed to deliver care. A charge is an administratively assigned price. Payment is what a payer allows. Patient out-of-pocket liability depends on benefit design, deductible, coinsurance, network status, and site of care. Value is the health outcome achieved per total resources consumed. A cheaper implant can be lower value if it increases bone loss, instability, loosening, or revision; an expensive feature is not high value merely because it is new.

Implants are a major facility-cost driver. Multicenter time-driven activity-based costing found that implants represented approximately 56% of anatomic and 62% of reverse TSA costs, with substantial interinstitutional variation (PMID: 32807371). A 2026 commercial-claims analysis reported historical mean implant prices of $5,928 for anatomic TSA and $8,720 for reverse TSA. Inflation-adjusted prices fell by 45.3% and 42.9%, respectively, from 2010 through 2022, yet patient out-of-pocket spending did not decline significantly (PMID: 41909784). These are dataset-specific estimates, not universal current acquisition prices.

Teaching Point: Implant-price reduction does not automatically reach the patient. Contract structure, facility payment, overhead, site of service, and benefit design determine where savings accrue.

Clinical leaders should manage price variation through transparent internal dashboards, competitive contracting, rational tray design, and a limited formulary of evidence-supported systems with an exception process. Standardization can improve team familiarity and purchasing leverage, but forced standardization becomes unsafe when it eliminates an augment, fixation option, stem length, or revision-compatible construct necessary for a patient’s anatomy. Platform convertibility has potential revision value, but it also creates vendor dependence and should not be purchased without examining actual retention rates, compatibility, and revision inventory.

Outpatient migration offers larger potential savings than marginal implant substitutions, but only when selection is sound. Systematic reviews support outpatient shoulder arthroplasty as safe and less costly in selected patients; commonly used criteria have included younger physiologic age, BMI below approximately 35 kg/m², absence of unstable cardiopulmonary disease, and reliable home support (PMID: 34757981). These are selection patterns, not absolute rules. Assess frailty, ASA class, diabetes, arrhythmia, pulmonary disease, obstructive sleep apnea, anticoagulation, prior VTE, operative complexity, travel distance, cognition, home stairs, caregiver availability, and access to urgent evaluation. Coverage in an ambulatory surgery center is permission, not proof of suitability.

MUST ACT: Never allow a lower facility payment or an insurer’s outpatient authorization to overrule a documented need for inpatient admission, extended observation, or postoperative support.

High-value protocols often save more than a downgraded implant. A typical antimicrobial pathway uses cefazolin 2 g IV within 60 minutes before incision—3 g for patients at least 120 kg—with redosing every four hours or after major blood loss. Vancomycin, commonly 15 mg/kg and started within 120 minutes, should be reserved according to local policy for documented MRSA colonization or an appropriate severe beta-lactam allergy. Cefazolin was associated with fewer shoulder periprosthetic infections than non-cefazolin alternatives in a large cohort (PMID: 35188900). Five-percent benzoyl peroxide applied for approximately three days can reduce Cutibacterium acnes burden, although reduction in cultures has not yet established a reduction in clinical PJI (PMID: 30054245).

Tranexamic acid is another inexpensive intervention. A common regimen is 1 g IV approximately 10 minutes before incision, adjusted or avoided for relevant renal impairment or contraindications. A meta-analysis of five randomized trials found less blood loss, drainage, and hemoglobin decline without a demonstrated increase in complications, although optimal dosing remains unsettled (PMID: 39702063). Multimodal analgesia—regional anesthesia when appropriate, scheduled acetaminophen, a patient-appropriate NSAID, ice, and limited rescue opioid—supports early mobilization and discharge.

Nuance: “Cost-conscious” means choosing the least costly clinically equivalent pathway. “Rationing” means withholding a clinically necessary difference. The former should be systematic and transparent; the latter requires explicit ethical scrutiny.

Shared decision-making should disclose meaningful differences in expected rotation, stability, activity restrictions, complication signatures, revision options, patient liability, and evidence certainty. Financial relationships with manufacturers must not be allowed to masquerade as clinical necessity.

Audience Poll: Which cost is most visible in your operating room—implant invoice, operating-room time, length of stay, readmission, rehabilitation, or revision—and which cost is actually measured?

Policy Initiatives that Influence Practice

%%FIG3%% The relevant US clinical guideline is the AAOS 2020 Management of Glenohumeral Joint Osteoarthritis clinical practice guideline, not an “AANA Class I” economic implant directive. The AAOS guideline supports anatomic TSA over hemiarthroplasty for primary osteoarthritis and considers anatomic or reverse TSA reasonable in selected patients with excessive glenoid bone loss or cuff dysfunction, while acknowledging limited comparative evidence. It does not mandate robotics, a manufacturer, or a cost-based implant choice (AAOS guideline).

Policy has most visibly changed the site of service. CPT 23472, which encompasses both anatomic and reverse total shoulder arthroplasty, left Medicare’s inpatient-only list in 2021. This permitted hospital-outpatient payment; it did not make every patient an outpatient. Medicare added CPT 23470 and 23472 to the ambulatory-surgery-center Covered Procedures List effective January 1, 2024 (CY 2024 OPPS/ASC policy summary). Inpatient admission remains appropriate when the expected hospital course and patient-specific medical necessity satisfy applicable rules, including the Two-Midnight framework.

Teaching Point: A payment classification answers “Where may Medicare pay for this procedure?” It does not answer “Where is this particular patient safest?”

The payment differential creates real pressure. In the July 2026 national unadjusted fee schedules, facility payment for CPT 23472 was approximately $17,914 in the hospital outpatient department and $13,912 in an ASC; geographic adjustment and other rules modify actual payment (CMS OPPS addenda, CMS ASC addenda). These figures are neither hospital costs nor patient charges. Because the payment is packaged and CPT 23472 does not distinguish anatomic from reverse constructs, higher implant acquisition cost compresses the facility margin.

Coverage documentation should be clinically useful even when payer requirements vary. Record the diagnosis, pain and disability using a reproducible measure, functional limitation, reasonable nonoperative treatment, imaging, cuff and deltoid status, glenoid deformity, rationale for anatomic versus reverse geometry, medical optimization, and site-of-care reasoning. Local coverage determinations apply only within their jurisdiction and should not be represented as universal national Medicare policy.

Prior authorization is another pressure point. Traditional Medicare’s national hospital-outpatient prior-authorization list does not currently include total shoulder arthroplasty, but Medicare Advantage and commercial plans frequently use plan-specific authorization. Beginning in 2026, CMS-0057-F requires many affected payers to issue expedited medical decisions within 72 hours and standard decisions within seven calendar days, provide a specific denial reason, and publish authorization metrics; FHIR-based API requirements primarily begin in 2027 (CMS-0057-F).

MUST ACT: Appeal a denial with patient-specific clinical evidence. “The surgeon prefers this implant” is weak; “CT demonstrates a defect for which standard reaming would remove supportive bone and perforate the vault” is a defensible medical-necessity argument.

Episode-payment policy also requires precision. BPCI Advanced included outpatient TSA within major joint replacement of the upper extremity beginning in 2023 and held participants accountable for a 90-day episode, but the model ended December 31, 2025 (CMS BPCI Advanced). The mandatory TEAM model began in 2026 but includes lower-extremity joint replacement, hip/femur fracture surgery, spinal fusion, coronary bypass, and major bowel procedures—not shoulder arthroplasty (CMS TEAM). Commercial or local shoulder bundles may still apply; there is no current national mandatory CMS shoulder bundle.

Registry participation can counterbalance short-term financial incentives by tracking implant, complication, revision, and patient-reported outcome data. The AAOS Shoulder & Elbow Registry—not the hip-and-knee-focused AJRR—is the relevant national platform. Registry evidence remains observational and incomplete, but it supports surveillance, benchmarking, and identification of unexpected failure signals.

Framework: Translate policy into four operational questions: Is the operation covered? Is the requested site safe? Is the documentation sufficient? Does the payment model reward or distort the clinical plan?

Audience Poll: Which policy most affects your practice today—site-of-service pressure, prior authorization, implant contracting, quality reporting, or episode-based payment?

Case Discussions: Balancing Cost and Care Quality

%%FIG4%% A defensible decision process follows pathology before price. First, confirm the indication and pain generator. Second, define soft-tissue function and three-dimensional bone anatomy. Third, choose anatomic or reverse geometry based on the reconstruction most likely to remain mechanically reliable. Fourth, select the least costly construct among clinically equivalent options. Finally, incorporate the entire episode: medical optimization, operating-room efficiency, infection and blood-loss prevention, discharge support, rehabilitation, complications, and revision.

Framework: Pathology → cuff and deltoid function → bone and instability → patient goals → episode-of-care value.

Consider a 58-year-old electrician with primary osteoarthritis, an intact cuff, a centered Walch A2 glenoid, strong metaphyseal bone, and high rotational demands. Anatomic TSA is usually the rational starting point. Reverse TSA would reduce dependence on future cuff integrity, but its constraint, stress-fracture risk, rotation profile, and lifetime revision pathway are relevant in a younger patient. A stemless humeral component may preserve bone, but it is optional rather than inherently superior. A conventional stem with excellent outcomes and a lower contracted price remains reasonable. Hemiarthroplasty should not be substituted solely to avoid glenoid-component cost because inferior pain relief and progressive glenoid erosion can erase the initial saving.

Now consider a 78-year-old with cuff-tear arthropathy, superior migration, pseudoparesis, an irreparable posterosuperior cuff, intact deltoid function, and disabling pain. Reverse TSA addresses the mechanism by creating a deltoid-powered fulcrum. A less expensive hemiarthroplasty does not recreate that fulcrum and leaves function dependent on deficient soft tissues. Here, choosing reverse geometry is not purchasing a luxury; it is paying for the defining therapeutic mechanism.

Teaching Point: The right comparison is not “Which implant costs less?” It is “Which clinically appropriate option is least costly over the patient’s likely episode and revision horizon?”

A third patient is 76 years old with cuff-intact osteoarthritis, a B3 glenoid, fixed stiffness, 25° of retroversion, posterior subluxation, osteoporosis, sleep apnea, atrial fibrillation on anticoagulation, and no adult caregiver at home. Reverse TSA may manage the bone loss and instability more predictably than aggressive corrective reaming for an anatomic component, but osteoporosis also raises acromial stress-fracture risk. An augmented baseplate may preserve native bone; navigation might reduce an outlier in this complex vault, but neither should be presented as proven to improve survivorship. The hospital outpatient department with overnight observation may be safer than an ASC despite the lower ASC payment.

Decision Point: Is the premium feature necessary for fixation or reconstruction, useful but optional, or merely convenient? Only the first category supports a strong medical-necessity appeal.

Fracture illustrates the same discipline. Many displaced proximal-humerus fractures can be treated nonoperatively; PROFHER found no two-year advantage for surgery across a broad surgical-neck-fracture population (PMID: 25756440). Conversely, for an independent older adult with an irreconstructible head-split or severely comminuted three- or four-part fracture, reverse TSA may outperform cheaper hemiarthroplasty because hemiarthroplasty depends heavily on tuberosity healing. A randomized study in patients older than 70 found better function and elevation with reverse TSA and required conversion of six hemiarthroplasties to reverse constructs (PMID: 25086490). Cost consciousness begins by avoiding an unnecessary operation, not by compromising a necessary one.

What should never be economized away includes sterile technique, adequate antibiotic prophylaxis, secure fixation, essential augmentation, trained personnel, a backup implant strategy, postoperative neurologic examination, or access to urgent evaluation. More defensible savings include vendor negotiation, eliminating unused trays, avoiding redundant disposables, efficient turnover, evidence-based TXA, multimodal analgesia, safe same-day discharge, and home rehabilitation for appropriately selected patients.

MUST ACT: New focal acromial or scapular-spine pain after reverse TSA—especially following increased strengthening—requires cessation of loading, sling protection, and evaluation for a stress fracture. Plain radiographs can be initially negative; CT may be necessary.

Nuance: Similar average revision-free survival does not mean that anatomic and reverse implants provide identical motion, complication patterns, or revision complexity. Shared decision-making must address the outcomes the individual patient values.

Audience Poll: Which finding most strongly shifts a cuff-intact B2 shoulder toward reverse TSA: age alone, poor cuff quality, uncorrectable posterior subluxation, fixed stiffness, or the hospital’s implant contract?

Case: Implant Choice Under Economic Constraints

Presentation: A 65-year-old right-hand-dominant maintenance supervisor reports 18 months of progressive right shoulder pain, crepitus, night waking, and inability to perform overhead work. He has completed activity modification, a supervised rehabilitation program, acetaminophen and an NSAID trial, and one glenohumeral corticosteroid injection five months ago. His insurer covers shoulder arthroplasty but denies robotic assistance and will authorize an augmented implant only after peer-to-peer review. He is primarily concerned about returning to work and limiting out-of-pocket expense.

Examination shows restricted active and passive elevation, external rotation to 10°, preserved external-rotation strength, a negative lag sign, intact deltoid contraction and axillary-nerve sensation, and no pseudoparesis. Cervical examination is nonprovocative. Grashey and axillary views demonstrate end-stage osteoarthritis with posterior decentering. Thin-cut CT shows a Walch B2 biconcave glenoid with approximately 18° of retroversion and substantial posterior humeral-head subluxation. MRI demonstrates an intact cuff with minimal fatty infiltration and a repairable subscapularis. His BMI is 31 kg/m², hemoglobin A1c is 7.2%, renal function is normal, and he has reliable home support.

MUST ACT: Do not reduce this case to “reverse costs more” or “anatomic preserves motion.” The decisive question is whether an anatomic glenoid can be supported and the humeral head recentered without excessive anterior reaming, joint-line medialization, vault perforation, or residual posterior instability.

For this patient, anatomic TSA offers native mechanics and a likely external-rotation advantage that matters for work. Reverse TSA offers semiconstrained stability and less dependence on long-term cuff integrity, but introduces acromial stress, instability, notching, and a different lifetime revision pathway. Evidence for cuff-intact B2 glenoids supports both operations in selected patients and does not establish universal reverse superiority (PMID: 37588714).

Three-dimensional templating is performed even though robotic assistance is denied. If conservative eccentric reaming can correct enough version while preserving supportive anterior subchondral bone and achieving complete component support, a cemented all-polyethylene glenoid is reasonable. If that correction would excessively medialize the joint or leave posterior support inadequate, a posteriorly augmented polyethylene glenoid provides a bone-preserving rationale. The appeal should include CT measurements, planned correction, predicted vault compromise with a standard component, and the clinical consequence of residual posterior loading. “Newer implant” or “surgeon preference” is insufficient justification.

If the contracted implant system offers a suitable augment, reliable instrumentation, established surveillance, and future revision options, there is no requirement to purchase a more expensive “premium” platform. Conversely, substituting an older metal-backed glenoid, unsupported standard component, or hemiarthroplasty merely to satisfy a price target would be clinically inequivalent. If templating shows that the humeral head cannot be reliably recentered—or if intraoperative inspection reveals unexpectedly poor cuff, subscapularis, or glenoid bone—conversion to reverse TSA should remain available.

Decision: After shared review, the provisional plan is conventional-instrumented anatomic TSA with a posteriorly augmented cemented all-polyethylene glenoid, provided intraoperative bone and stability confirm the plan. Reverse components are available as backup. The patient understands that heavy occupational loading may need modification regardless of implant and that avoiding an early failure is more valuable than minimizing the implant invoice.

The perioperative pathway emphasizes low-cost interventions with direct clinical value. Because the injection occurred five months earlier, surgery is outside the interval most consistently associated with increased PJI; contemporary meta-analysis supports avoiding elective arthroplasty within approximately three months of an ipsilateral corticosteroid injection when feasible (PMID: 39791093). The patient uses 5% benzoyl peroxide on the operative shoulder for three days according to institutional instructions, recognizing that culture reduction is not proof of fewer PJIs. He receives cefazolin 2 g IV within 60 minutes before incision, with four-hour redosing if needed, and 1 g IV tranexamic acid approximately 10 minutes before incision after contraindication review.

Analgesia combines an anesthesiologist-directed regional block, acetaminophen—commonly 650–1,000 mg every eight hours with a conservative maximum of 3 g/day—an NSAID only if renal, gastrointestinal, and cardiovascular status permit, ice, and a small supply of rescue opioid with bowel prophylaxis. Sequential compression and early ambulation are routine; pharmacologic VTE prophylaxis is individualized because shoulder-specific thromboembolic risk and evidence differ from hip and knee arthroplasty.

If the subscapularis repair is secure, rehabilitation begins with hand, wrist, elbow, and scapular motion plus protected passive elevation. The sling is used for approximately four to six weeks. External rotation is limited to the repair-specific safe zone, often 20°–30° initially; extension, active internal rotation, pushing from a chair, and weight bearing through the arm are avoided. Active-assisted motion generally begins around weeks four to six, active motion around weeks six to eight, and strengthening around weeks ten to twelve, contingent on examination and radiographs.

Teaching Point: Financial pressure is best addressed by eliminating nonbeneficial variation while protecting the elements that determine fixation, stability, infection prevention, and recovery.

Postoperatively, progressive drainage, fever, unexpected stiffness, new neurologic deficit, loss of internal-rotation strength, recurrent posterior decentering, or persistent unexplained pain triggers evaluation for infection—including indolent C. acnes infection—subscapularis failure, fracture, instability, component malposition, or loosening. A low-cost pathway is successful only if it preserves surveillance and rapid access to care.

Tonight on Shift

• [ ] Confirm the diagnosis, failed nonoperative care, functional goals, and dominant pain generator.
• [ ] Document cuff, subscapularis, deltoid, axillary-nerve, glenoid, and bone-quality findings before choosing geometry.
• [ ] Use CT-defined reconstructibility—not age or implant price alone—to choose anatomic versus reverse TSA.
• [ ] Distinguish planning, PSI, navigation, and robotics; verify registration and retain a manual bailout plan.
• [ ] Match site of care, prophylaxis, analgesia, and discharge support to patient risk rather than payer preference.
• [ ] Escalate drainage, neurologic change, instability, focal acromial pain, or unexplained stiffness before labeling recovery “routine.”

Read this seminar as Markdown · All seminars · Lecture library · Question bank